Select Publications
Journal articles
, 2025, 'Effectiveness of Biologic Therapy in Hidradenitis Suppurativa: Real-World Clinical Outcomes and Lipid Profile Evaluation', Australasian Journal of Dermatology, http://dx.doi.org/10.1111/ajd.14592
, 2025, 'Pilot Study of Tildrakizumab in the Treatment of Stable Non-Segmental Vitiligo', JEADV Clinical Practice, http://dx.doi.org/10.1002/jvc2.70113
, 2025, 'Quality of Life Measurement in Autoimmune Blistering Diseases: Mutual Position Statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Autoimmune Blistering Diseases', International Journal of Dermatology, http://dx.doi.org/10.1111/ijd.17964
, 2024, 'A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council', British Journal of Dermatology, 192, pp. 135 - 143, http://dx.doi.org/10.1093/bjd/ljae342
, 2024, '“Quality of Life in Epidermolysis Bullosa” and “Epidermolysis Bullosa Burden of Disease”: Italian translation, cultural adaptation, and pilot testing of two disease-specific questionnaires', Italian Journal of Pediatrics, 50, http://dx.doi.org/10.1186/s13052-024-01657-2
, 2024, 'A new dawn for orphan diseases in dermatology: The transformative potential of digital twins', Journal of the European Academy of Dermatology and Venereology, 38, pp. 2309 - 2310, http://dx.doi.org/10.1111/jdv.20062
, 2024, 'Digital twins in dermatology, current status, and the road ahead', Npj Digital Medicine, 7, http://dx.doi.org/10.1038/s41746-024-01220-7
, 2024, 'Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)', Advances in Therapy, 41, pp. 4418 - 4432, http://dx.doi.org/10.1007/s12325-024-02992-w
, 2024, 'The future of digital pills and their potential use in dermatological clinical trials', Journal of the European Academy of Dermatology and Venereology, 38, pp. 2314 - 2315, http://dx.doi.org/10.1111/jdv.20224
, 2024, 'A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists', Clinics in Dermatology, 42, pp. 723 - 726, http://dx.doi.org/10.1016/j.clindermatol.2024.05.008
, 2024, 'Establishing minimal clinically important differences for the Pemphigus Disease Area Index', British Journal of Dermatology, 191, pp. 823 - 831, http://dx.doi.org/10.1093/bjd/ljae283
, 2024, 'Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial', Eclinicalmedicine, 77, http://dx.doi.org/10.1016/j.eclinm.2024.102900
, 2024, 'Keratosis pilaris treatment paradigms: Assessing effectiveness across modalities', Clinical and Experimental Dermatology, 49, pp. 1105 - 1117, http://dx.doi.org/10.1093/ced/llae066
, 2024, 'Cross-sectional burden-of-illness study in atopic dermatitis (MEASURE-AD) in Australia and New Zealand reveals impacts on well-being', Australasian Journal of Dermatology, 65, pp. e145 - e155, http://dx.doi.org/10.1111/ajd.14308
, 2024, 'Dermatology Journal Advisory Boards and editorial independence', Jaad International, 16, pp. 224 - 236, http://dx.doi.org/10.1016/j.jdin.2023.08.001
, 2024, 'Letter to the editor in reply to “A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists”', Clinics in Dermatology, 42, pp. 526 - 527, http://dx.doi.org/10.1016/j.clindermatol.2024.07.002
, 2024, 'Sustained clinical remission for 5 years in severe epidermolysis bullosa acquisita following rituximab infusions', Journal of the European Academy of Dermatology and Venereology, 38, pp. e747 - e749, http://dx.doi.org/10.1111/jdv.19863
, 2024, 'Patient-reported outcomes and safety in adolescent and adult atopic dermatitis patients treated with dupilumab: real-world insights one year into the GLOBOSTAD multinational prospective observational study', BRITISH JOURNAL OF DERMATOLOGY, 191, http://dx.doi.org/10.1093/bjd/ljae266.016
, 2024, 'Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study', Journal of Investigative Dermatology, 144, pp. 1762 - 1771.e6, http://dx.doi.org/10.1016/j.jid.2024.02.023
, 2024, 'Gender equity in academic dermatology: Problems aplenty, yet paths ahead', Journal of the European Academy of Dermatology and Venereology, 38, pp. 1504 - 1513, http://dx.doi.org/10.1111/jdv.20027
, 2024, 'Phenotypic differences in intermediate generalized junctional epidermolysis bullosa with homozygous LAMC2 mutation and a potential genetic modifier', Journal of the European Academy of Dermatology and Venereology, 38, pp. e719 - e721, http://dx.doi.org/10.1111/jdv.19859
, 2024, 'Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT (Advances in Therapy, (2024), 41, 7, (2991-3002), 10.1007/s12325-024-02810-3)', Advances in Therapy, 41, pp. 3014 - 3015, http://dx.doi.org/10.1007/s12325-024-02886-x
, 2024, 'Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT', Advances in Therapy, 41, pp. 2991 - 3002, http://dx.doi.org/10.1007/s12325-024-02810-3
, 2024, 'Physician-assessed effectiveness, patient-reported outcomes, and safety in adult and adolescent patients with atopic dermatitis treated with dupilumab: real-world insights 1 year into the GLOBOSTAD multinational prospective observational study', BRITISH JOURNAL OF DERMATOLOGY, 191, pp. I56 - I57, http://dx.doi.org/10.1093/bjd/ljae090.115
, 2024, 'S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology', Journal of the European Academy of Dermatology and Venereology, 38, pp. 1006 - 1023, http://dx.doi.org/10.1111/jdv.19880
, 2024, 'Editorial: Pemphigus and pemphigoid diseases: in memoriam Detlef Zillikens', FRONTIERS IN IMMUNOLOGY, 15, http://dx.doi.org/10.3389/fimmu.2024.1426834
, 2024, 'Impairment of sexual function in patients with pemphigus', Journal of the European Academy of Dermatology and Venereology, 38, pp. 643 - 644, http://dx.doi.org/10.1111/jdv.19882
, 2024, 'The road to publication: Advice from journal editors', Journal of the American Academy of Dermatology, 90, pp. 707 - 710, http://dx.doi.org/10.1016/j.jaad.2023.11.038
, 2024, 'Physician-assessed effectiveness and patient-reported outcomes in adult and adolescent patients with atopic dermatitis treated with dupilumab: real-world insights 1 year into the GLOBOSTAD multinational prospective observational study', BRITISH JOURNAL OF DERMATOLOGY, 190, pp. II34 - II34, http://dx.doi.org/10.1093/bjd/ljad498.036
, 2024, 'Meeting report: Women’s Dermatology Society Forum at the 25th World Congress of Dermatology, Singapore, 2023', International Journal of Women S Dermatology, 10, http://dx.doi.org/10.1097/JW9.0000000000000125
, 2024, 'Overview of Clinical Trials With Efgartigimod in Autoimmune Blistering Diseases: Pemphigus Vulgaris and Pemphigus Foliaceus (ADDRESS and ADDRESS+) and Bullous Pemphigoid (BALLAD and BALLAD+)', SKIN The Journal of Cutaneous Medicine, 8, pp. s345 - s345, http://dx.doi.org/10.25251/skin.8.supp.345
, 2024, 'A Case of Hidradenitis Suppurativa Responsive to Testosterone Replacement Therapy', Indian Dermatology Online Journal, 15, pp. 854 - 855, http://dx.doi.org/10.4103/idoj.idoj_653_23
, 2024, 'Atypical fixed drug eruption in confetti due to paracetamol', Dermatologica Sinica, 42, pp. 160 - 161, http://dx.doi.org/10.4103/ds.DS-D-23-00161
, 2024, 'Environmental triggers of pemphigus vulgaris and bullous pemphigoid: a case control study', Frontiers in Medicine, 11, http://dx.doi.org/10.3389/fmed.2024.1441369
, 2024, 'Predatory Conferences and Journals in Dermatology Are Black Widow Parties', Skinmed, 22, pp. 407 - 408
, 2024, 'The potential of Bruton’s tyrosine kinase (BTK) inhibitors in the pharmacotherapeutic management of immune and dermatological disease', Expert Opinion on Pharmacotherapy, 25, pp. 1657 - 1665, http://dx.doi.org/10.1080/14656566.2024.2393280
, 2024, '274 Oleogel-S10 reduces dressing changes burden and associated costs in patients with epidermolysis bullosa', Journal of Investigative Dermatology, 144, pp. S47 - S47, http://dx.doi.org/10.1016/j.jid.2024.06.290
, 2024, 'Evaluation of Skin of Color Publication Trends over the Past Two Decades in the Journal of the American Academy of Dermatology (vol 89, pg 614, 2023)', JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 90, pp. 881 - 881, http://dx.doi.org/10.1016/j.jaad.2024.01.005
, 2023, 'Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: A 30-month experience', Clinical and Experimental Dermatology, 48, pp. 1266 - 1269, http://dx.doi.org/10.1093/ced/llad215
, 2023, 'Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial', Journal of the European Academy of Dermatology and Venereology, 37, pp. e1211 - e1214, http://dx.doi.org/10.1111/jdv.19195
, 2023, 'Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study', British Journal of Dermatology, 189, pp. 392 - 399, http://dx.doi.org/10.1093/bjd/ljad182
, 2023, 'The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid', Journal of Investigative Dermatology, 143, pp. 1868 - 1871, http://dx.doi.org/10.1016/j.jid.2023.03.1673
, 2023, 'Evaluation of skin of color publication trends over the past 2 decades in the Journal of the American Academy of Dermatology', Journal of the American Academy of Dermatology, 89, pp. 614 - 616, http://dx.doi.org/10.1016/j.jaad.2023.05.036
, 2023, 'Immunisation status during biologic therapy for hidradenitis suppurativa and psoriasis', JEADV Clinical Practice, 2, pp. 549 - 552, http://dx.doi.org/10.1002/jvc2.182
, 2023, 'Interventions for bullous pemphigoid', Cochrane Database of Systematic Reviews, 2023, http://dx.doi.org/10.1002/14651858.CD002292.pub4
, 2023, 'A Review of the Scoring and Assessment of Keratosis Pilaris', Skin Appendage Disorders, 9, pp. 241 - 251, http://dx.doi.org/10.1159/000529487
, 2023, 'Dermatoethics: Nepotism in dermatology residencies', Journal of the American Academy of Dermatology, 89, pp. 193 - 194, http://dx.doi.org/10.1016/j.jaad.2022.01.011
, 2023, 'Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1366 - 1374, http://dx.doi.org/10.1111/jdv.18914
, 2023, 'The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial', Lancet Rheumatology, 5, pp. e413 - e421, http://dx.doi.org/10.1016/S2665-9913(23)00131-5
, 2023, 'Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study', BRITISH JOURNAL OF DERMATOLOGY, 188, http://dx.doi.org/10.1093/bjd/ljad113.144